Cargando…
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions
Improvements in survival of patients with breast cancer have been attributed to the development of agents that target key components of dysregulated pathways involved in oncogenesis and progression of breast cancer. Aberrant mammalian target of rapamycin (mTOR) activation has been implicated in onco...
Autor principal: | Yardley, Denise A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579426/ https://www.ncbi.nlm.nih.gov/pubmed/23492649 http://dx.doi.org/10.4137/BCBCR.S10071 |
Ejemplares similares
-
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012) -
mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019) -
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018) -
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020) -
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)